

Evolution of Imaging-Based Diagnosis

York Pei, MD, FRCPC, FACP
Division of Nephrology
University Health Network
University of Toronto



UNIVERSITY OF
TORONTO



Disclosure of Interests

Consultancy to:

- Otsuka
- Novartis
- Genzyme/Sanofi

Acknowledgments

- Peter Hwang, John Conklin, Winnie Chan, Ning He, Kairong Wang, Mosfata Atri, Masoom Haider
- Jamie Sundsbak, Christina Heyer, Peter Harris
- Grants from Physicians Services Incorporated (PSI) Foundation and Canadian Institutes of Health Research (Y.P.) and from NIH to Mayo PKD Genetics Core (P.H.)




Background

- Most common hereditary kidney disease (~1/500-1000 births)
- ~70-75% and ~25-30% of cases are due to mutations in *PKD1* and *PKD2*, respectively¹
- Clinical manifestations of *PKD1* and *PKD2* overlap completely
- *PKD2* is much milder compared to *PKD1* with a delayed onset of ESRD of ~20 years²
- Hypomorphic *PKD1* mutations are a common cause of mild disease

1. Adv Chronic Kidney Disease 17: 140-152, 2010
2. Lancet 353: 103-107, 1999

Cyst formation is age-dependent



Age: 29 years

vs



40 years

Current Diagnosis of ADPKD

- Pre-symptomatic Dx of at-risk family members is most commonly made by renal U/S which is:
 - based on age-dependent criteria
 - inexpensive and widely available
- CT/MRI are also used for disease exclusion in at-risk potential LRTx donors. However, the validity of this approach is unclear
- Gene-based testing reserved for atypical cases, de novo disease, equivocal imaging results, and disease exclusion in younger at-risk subjects

Diagnostic Testing (I)

	D(+)	D(-)
T(+)	T.P.	F.P.
T(-)	F.N.	T.N.

Diagnostic Testing (II)

	D(+)	D(-)
T(+)	a	b
T(-)	c	d

Diagram illustrating a 2x2 contingency table for diagnostic testing. The columns represent the actual disease status (D(+), D(-)) and the rows represent the test result (T(+), T(-)). The cells contain the counts: a (True Positive), b (False Positive), c (False Negative), and d (True Negative). Blue arrows point from the column headers to the corresponding columns, and from the row headers to the corresponding rows. A large orange watermark 'KIDNEY' is overlaid on the table.

$$\text{SEN} = a/(a+c)$$

$$\text{SPEC} = d/(b+d)$$

$$\text{FNR} = 1-\text{SEN} = c/(a+c)$$

$$\text{FPR} = 1-\text{SPEC} = b/(b+d)$$

Diagnostic Testing (III)

	D(+)	D(-)
T(+)	a	b
T(-)	c	d

$$\text{PPV} = a/(a+b)$$

$$\text{NPV} = d/(c+d)$$

U/S Diagnostic Criteria for PKD1

Age	SEN (%)	SPEC (%)	PPV (%)	NPV (%)
< 30 yrs ¹	88.5	100	100	96.6
30-59 yrs ²	100	100	100	100
≥ 60 yrs ³	100	100	100	100

Ravine criteria:

1. A total of 2 cysts in both kidneys
2. 2 or more cysts in each kidney
3. 4 or more cysts in each kidney

- Do these criteria perform equally well in PKD2?

Unified Ultrasound Diagnostic Criteria for ADPKD

Y. Pei¹, A. Dupuis², A. Paterson², R. Magistroni^{1,3},
E. Dicks⁴, P. Parfrey⁴, B. Cramer⁴, E. Coto⁵, R.
Torra⁶, J.L. SanMillan⁷, M. Breuning⁸, D. Peters⁸,
D. Ravine⁹

¹University Health Network, Toronto, Canada; ²Hospital for Sick Children, Toronto, Canada; ³University of Modena, Modena, Italy; ⁴Memorial University, St. Johns, Newfoundland, Canada; ⁵Hospital Central de Asturias, Oviedo, Spain; ⁶Fundacio Puigvert, Barcelona, Spain; ⁷Unidad de Genetica Molecular, Hospital Ramon y Cajal, Madrid, Spain; ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹University of Western Australia, Perth, Australia

JASN 20: 205-212, 2009



Study Design

- Retrospective study of 58 PKD1 and 39 PKD2 families from 8 international PKD research centers
 - 577 subjects borne with 50% risk of PKD1
 - 371 subjects borne with 50% risk of PKD2
- U/S performed using a 3 or 5 MHz sector probe with scanners from >10 years ago
- Molecular Dx (“gold standard”) by either linkage or gene-based mutation screen of PKD1 and PKD2
- U/S and molecular studies collated to evaluate the performance of different age-specific diagnostic criteria for PKD1, PKD2, and unknown gene type



Unified Ultrasound Diagnostic Criteria

Age (yrs)	PKD1	PKD2	Unknown Gene Type
15-30 ¹	PPV=100% SEN=94.3%	PPV=100% SEN=69.5%	PPV=100% SEN=81.7%
30-39 ¹	PPV=100% SEN=96.6%	PPV=100% SEN=94.9%	PPV=100% SEN=95.5%
40-59 ²	PPV=100% SEN=92.6%	PPV=100% SEN=88.8%	PPV=100% SEN=90%

1. A total of 3 cysts in both kidneys
2. 2 or more cysts in each kidney

JASN 20: 205-212, 2009



Exclusion of ADPKD

by absence of renal cyst

Age (yrs)	PKD1	PKD2	Unknown Gene Type
15-30	NPV=99.1% SPEC=97.6%	NPV=83.5% SPEC=96.6%	NPV=90.8% SPEC=97.1%
30-39	NPV=100% SPEC=96%	NPV=96.8% SPEC=93.8%	NPV=98.3% SPEC=94.8%
40-59 ²	NPV=100% SPEC=93.9%	NPV=100% SPEC=93.7%	NPV=100% SPEC=93.9%

JASN 20: 205-212, 2009




Unified Ultrasound Diagnostic Criteria

Limitations


- Applies only to at-risk subjects with +ve family Hx (i.e. borne with 50% risk)
- Disease exclusion is not possible in younger at-risk subjects (<40 years of age)
- Results may not be generalizable to new generations of U/S scanners

Evolution of Imaging-Based Diagnosis of ADPKD



Toronto Radiologic Imaging Studies of Polycystic Kidney Disease (TRISP)

June 2010-May 2013



Methods: Imaging Techniques

- **MRI:** Performed at TGH using a respiratory triggered T2 weighted axial fat suppressed fast spin echo sequence on a 1.5T scanner. Cyst number was enumerated (by J.C. and M.H.) if cyst count/kidney was <10 . For a kidney with >10 cysts, enumeration was not performed.
- **USG:** Performed at TGH by experienced technicians (supervised by M.A.) using a Toshiba Aplio (with L6 MHz and C3.5MHz probes) or Philips IU22 (with C1-5 MHz and L4-8 MHz probes). Cyst number <10 /kidney was enumerated for each kidney. For a kidney with >10 cysts, enumeration was not performed.


Methods: Molecular Diagnosis

- Direct sequencing of all coding regions and splice sites of *PKD1* and *PKD2* in an affected family member of the proband. In any mutation-negative case, MLPA was performed to detect large gene rearrangements
- For hypomorphic *PKD1* mutations, segregation analysis was performed with additional affected and older (>40 years) unaffected family members, whenever possible
- DNA samples of test subjects were then screened for their family-specific mutation by sequencing or MLPA to define the disease status

Characteristics of Study Subjects

	PKD1 Truncating Mutations	PKD1 Hypomorphic Mutations	PKD2 Mutations	Control
Total, N (%)	57 (52)	25 (21)	29 (27)	45
Age, 16-29, N (%)	37 (65)	13 (48)	14 (48)	32 (71)
30-40, N (%)	20 (35)	12 (52)	15 (52)	13 (29)
Male, N (%)	25 (44)	13 (52)	10 (35)	23 (51)
Disease status				
Affected, N (%)	35 (61)	21 (87)	18 (62)	
Unaffected, N (%)	22 (39)	4 (13)	11 (38)	45
TKV (ml) (median)				
Affected	806*	476	424	N/A
Unaffected	304	279	310	307
S-[Cr] (μM)	79 [50-120]	79 [56-98]	66 [50-85]	

Total Cyst Count by Disease Status



*25 y.o. male with 15 and 18 cysts in each kidney by MRI (max diameter 5-6 mm), but no cyst on USG. He carried a hypomorphic *PKD1* mutation (i.e. A2752P) which segregated in a family of 4 affected with mild ADPKD. His BMI was 35.6

*USG detected 3 cysts in each of 2 male subjects (36 & 40y). However, MRI showed ≤ 2 cysts in these subjects and their molecular diagnosis was negative.

#30 y.o. male with 6 cysts in his right kidney by USG, a total of 10 renal cysts (6 in RK and 4 in LK) by MRI, but negative for a *PKD2* (IVS5+1G>A) mutation identified in his family.

Total Cyst number by USG vs MRI

At-Risk Subjects

MRI	USG									
	0	1	2	3	4	5-10	11-20	>20		
0	19	3	1	1*						24
1	6									6
2	3	1		1*						5
3	1									1
4										0
5-10						1*				1
11-20							1			1
>20	1#						1	1	70	73
	30	4	1	2	0	2	2	70		111

Controls

MRI	USG									
	0	1	2	3	4	5-10	11-20	>20		
0	37	3								40
1	2	1								3
2	1									1
3			1							1
4										0
5-10										0
11-20										0
>20										0
	40	4	1	0	0	0	0	0	0	45

Blue and red color denote affected and unaffected subjects, respectively

*False +ve Dx by USG using the criterion of 3 cysts in both kidneys

#False -ve Dx by USG in a subject with poor body habitus

Discordant Cases

ID	Age	Disease status	Mutation	MRI, RK	MRI, LK	USG, RK	USG, LK	Comment
AC [#]	25	<i>PKD1</i> (A)	p.Ala2752Asp	15	18	0	0	Cyst size 2-6 mm on MRI; BMI 35.6 (suboptimal USG)
CW*	30	<i>PKD2</i> (ARUA)	IVS5+1G>A	6	4	6	0	Cyst size 2-10 mm on MRI and USG
CW*	40	<i>PKD1</i> (ARUA)	p.Pro3551fs111X	1	1	2	1	Cyst size 2-6 mm on MRI and USG
PF*	36	<i>PKD2</i> (ARUA)	p.Val569fs3X	0	0	3	0	Cyst size 2-5 mm on USG

Performance Characteristics of USG

Age group (yr)	Diagnostic criterion	Study subjects	SEN	SPEC	PPV	NPV
15-29		(Affected, n=38; Unaffected, n=58)				
	≥1 renal cyst	Present study	0.97	0.85	0.80	0.98
		Pei et al (2009)	0.89	0.97	0.97	0.91
	≥2 renal cysts	Present study	0.97	0.95	0.93	0.98
		Pei et al (2009)	0.99	0.88	0.99	0.88
	≥3 renal cysts	Present study	0.97	0.98	0.97	0.98
		Pei et al (2009)	0.82	1.00	0.86	1.00
	≥2 cysts in each kidney	Present study	0.97	1.00	1.00	0.98
		Pei et al (2009)	NA	NA	NA	NA
	30-40		(Affected, n=36; Unaffected=24)			
≥1 renal cyst		Present study	1.00	0.83	0.90	1.00
		Pei et al (2009)	0.98	0.95	0.94	0.98
≥2 renal cysts		Present study	1.00	0.92	0.95	1.00
		Pei et al (2009)	0.96	0.98	0.98	0.97
≥3 renal cysts		Present study	1.00	0.92	0.95	1.00
		Pei et al (2009)	0.96	1.00	1.00	0.96
≥2 cysts in each kidney		Present study	1.00	1.00	1.00	1.00
	Pei et al (2009)	0.83	1.00	0.88	1.00	

Performance Characteristics of MRI

Age group (yr)	Diagnostic criterion	No. of Affected	No. of Unaffected	SEN	SPEC	PPV	NPV
15-29		N=38	N=58				
	≥1 renal cyst	38	11	1.00	0.81	0.78	1.00
	≥2 renal cysts	38	4	1.00	0.93	0.91	1.00
	≥3 renal cysts	38	2	1.00	0.97	0.95	1.00
	≥5 renal cysts	38	1	1.00	0.98	0.97	1.00
	>10 renal cysts	38	0	1.00	1.00	1.00	1.00
	≥2 cysts in each kidney	38	1	1.00	0.98	0.97	1.00
30-40		N=36	N=24				
	≥1 renal cyst	36	7	1.00	0.71	0.84	1.00
	≥2 renal cysts	36	5	1.00	0.79	0.88	1.00
	≥3 renal cysts	36	1	1.00	0.96	0.97	1.00
	≥5 renal cysts	36	0	1.00	1.00	1.00	1.00
	>10 renal cysts	36	0	1.00	1.00	1.00	1.00
	≥2 cysts in each kidney	36	0	1.00	1.00	1.00	1.00

Imaging-Based Diagnosis of ADPKD

Concluding Remarks

- MRI is highly sensitive and specific for early Dx and exclusion of ADPKD
- USG using modern scanners performed better than expected with results rivaling those by MRI. However, it is both operator and center-dependent and may be influenced by body habitus of test subjects
- Revision of current USG Dx criteria is needed to reflect improved imaging resolution of new scanners. Pending replication, our USG results should not be generalized to other centers at this time



Evolution of Imaging-based diagnosis of ADPKD



Evolution of Imaging-Based Diagnosis

- How and when should ultrasound, CT (contrast-enhanced) or MRI be used to diagnose ADPKD?
- Are the current US-based criteria for diagnosis and disease exclusion appropriate?
- Specific evaluation of ADPKD living-related donors?
- What criteria should be used for high-resolution US and what are its potential barriers?
- Is there any role for imaging-based diagnosis of ADPKD in subjects without a family history?

